The paper presents the results of three randomized trials for adjuvant chemo- and immunotherapy in malignant melanoma clinical stage II: 770 patients were treated by surgery, surgery + DTIC, surgery + BCG or surgery + DTIC + BCG, 248 patients were treated by surgery or surgery + poly-U-A; 40 patients were treated by surgery or surgery + vinblastine/bleomycine/cisplatinum. Neither the recidive free interval nor the survival could be enhanced by surgically adjuvant chemo- and immunotherapy in this group of patients.